Enovis Corporation $ENOV Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP grew its holdings in Enovis Corporation (NYSE:ENOV) by 130.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 604,500 shares of the company’s stock after acquiring an additional 342,556 shares during the quarter. Quantinno Capital Management LP’s holdings in Enovis were worth $13,752,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Arax Advisory Partners purchased a new position in shares of Enovis during the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC raised its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Danske Bank A S purchased a new stake in Enovis during the 3rd quarter valued at approximately $64,000. iSAM Funds UK Ltd acquired a new stake in Enovis during the 3rd quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. acquired a new stake in Enovis during the 3rd quarter worth approximately $90,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Insider Activity at Enovis

In related news, insider Oliver Engert bought 1,200 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ENOV shares. BMO Capital Markets began coverage on Enovis in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $29.00 target price on the stock. UBS Group restated a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Finally, BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.86.

Enovis Price Performance

Shares of ENOV opened at $29.22 on Monday. Enovis Corporation has a twelve month low of $19.14 and a twelve month high of $34.28. The stock’s 50 day moving average is $24.06 and its two-hundred day moving average is $23.80. The firm has a market capitalization of $1.68 billion, a PE ratio of -1.47 and a beta of 1.34. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts anticipate that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.